We observed that M002-treated CD4+ T cells were more capable of killing GSC005 tumor cells than CD4+ T cells from the saline control at all effector-to-target (E/T) ratios at both 14 and 35 days post-treatment (Fig. 3b, c). This evidence concerns the gene CD4 and neoplasm.